GlassScriptPhysician profile
Jose Alemar
NPI 1154302156
$21,388.14
in general payments reported to CMS, 2019-2025
80 companies · $12K in 2025
The $12K reported for 2025 was more than what 83% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $106 · 2021: $192 · 2022: $706 · 2023: $2,461 · 2024: $5,101 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Long Term Medical Supply Or Device Loan: $2,097 · Honoraria: $2,000 · Consulting Fee: $1,645 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $880 · Education: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,641.10 |
| Long Term Medical Supply Or Device Loan | $2,096.66 |
| Honoraria | $2,000.00 |
| Consulting Fee | $1,645.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $880.00 |
| Education | $479.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,754.27 | 2019-2025 | Tecvayli, Talvey, Rybrevant |
| Novartis Pharmaceuticals Corporation | $2,886.89 | 2019-2025 | |
| Immunocore Limited | $2,179.42 | 2025 | Kimmtrak |
| Pfizer INC. | $1,038.54 | 2019-2025 | |
| Gilead Sciences, INC. | $639.52 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $540.26 | 2019-2025 | |
| Celgene Corporation | $485.62 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $475.50 | 2023-2025 | Jakafi, Monjuvi, Monjuvi |
| Abbvie INC. | $474.80 | 2022-2025 | Epkinly, Venclexta |
| Exelixis INC. | $471.29 | 2021-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $451.46 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Daiichi Sankyo INC. | $413.29 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Galvanize Therapeutics, INC | $378.57 | 2025 | Aliya System |
| Karyopharm Therapeutics INC. | $357.88 | 2023-2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $329.16 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $326.70 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| E.R. Squibb & Sons, L.L.C. | $319.54 | 2019-2025 | Opdivo, Krazati |
| Amgen INC. | $314.27 | 2019-2025 | Kyprolis, Imdelltra (Amg757), Blincyto |
| Seagen INC. | $289.72 | 2023-2025 | Adcetris, Tukysa, Padcev |
| Blueprint Medicines Corporation | $275.06 | 2023-2024 | Ayvakit |
| Kite Pharma, INC. | $269.69 | 2021-2025 | Yescarta |
| Genentech USA, INC. | $250.72 | 2021-2025 | Tecentriq, Venclexta, Itovebi |
| Glaxosmithkline, LLC. | $230.98 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Janssen Scientific Affairs, LLC | $205.24 | 2025 | Talvey, Carvykti, Tecvayli |
| Pharmaessentia USA Corporation | $204.08 | 2024-2025 | Besremi |
| Sobi, INC | $185.38 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.71 | 2023-2025 | Alunbrig, Vpriv, Fruzaqla |
| Tempus Ai, INC | $174.81 | 2025 | Xt Cdx |
| Astellas Pharma US INC | $170.21 | 2019-2025 | Xtandi, Padcev |
| Adaptive Biotechnologies Corporation | $168.51 | 2024-2025 | Clonoseq |
| Servier Pharmaceuticals LLC | $143.63 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $136.63 | 2024-2025 | Myrisk |
| Array Biopharma INC | $131.09 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Lilly USA, LLC | $121.26 | 2023-2025 | Verzenio, Jaypirca |
| Azurity Pharmaceuticals, INC. | $117.95 | 2024-2025 | Vivimusta, Danziten |
| Bayer Healthcare Pharmaceuticals INC. | $112.16 | 2022-2025 | |
| Eisai INC. | $105.06 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $104.20 | 2023-2025 | Onivyde, Somatuline Depot |
| Regeneron Healthcare Solutions, INC. | $98.53 | 2025 | Libtayo, Lynozyfic |
| Sun Pharmaceutical Industries INC. | $90.14 | 2025 | |
| Beone Medicines USA, INC. | $89.96 | 2025 | Tevimbra, Brukinsa |
| Taiho Oncology, INC. | $88.16 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $87.56 | 2023-2025 | Monoferric |
| Stemline Therapeutics INC. | $83.65 | 2023-2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $81.95 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Cti Biopharma Corp. | $76.46 | 2022 | |
| Stryker Corporation | $73.54 | 2023 | Optablate |
| Tersera Therapeutics LLC | $69.62 | 2023-2024 | Zoladex |
| Sumitomo Pharma America, INC. | $66.60 | 2023-2025 | Orgovyx |
| Legend Biotech USA INC. | $63.61 | 2025 | Carvykti |
| Acrotech Biopharma INC. | $59.22 | 2022-2024 | Ryzneuta, Beleodaq |
| Dendreon Pharmaceuticals LLC | $57.14 | 2023-2025 | Provenge |
| Puma Biotechnology, INC. | $56.14 | 2022-2025 | |
| Springworks Therapeutics, INC. | $52.56 | 2024-2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $50.71 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $50.11 | 2024-2025 | Avastin, Alymsys |
| Immunogen, INC. | $49.92 | 2023 | Elahere |
| Beigene USA, INC. | $49.43 | 2024-2025 | Brukinsa |
| Fennec Pharmaceuticals, INC. | $49.34 | 2024-2025 | Pedmark, Fyarro |
| Janssen Pharmaceuticals, INC | $46.35 | 2019 | |
| Accord Healthcare, INC. | $46.32 | 2025 | |
| Mirati Therapeutics, INC. | $45.20 | 2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $44.66 | 2022 | |
| Jazz Pharmaceuticals INC. | $36.65 | 2025 | |
| Alexion Pharmaceuticals, INC. | $35.58 | 2025 | Ultomiris |
| Caris Mpi, INC. | $32.19 | 2025 | Mi Cancer Seek |
| Genmab U.S., INC. | $29.64 | 2023 | Epkinly |
| Syndax Pharmaceuticals, INC. | $24.54 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.71 | 2025 | |
| Geron Corporation | $22.92 | 2025 | Rytelo |
| Emd Serono, INC. | $21.26 | 2024 | |
| Kyowa Kirin, INC. | $20.14 | 2024 | Poteligeo |
| Csl Behring | $18.45 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.20 | 2023 | Givlaari |
| Apellis Pharmaceuticals, INC. | $16.71 | 2024 | Empaveli |
| Helsinn Therapeutics (U.S.), INC. | $14.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.01 | 2019 | |
| Secura Bio, INC. | $11.20 | 2022 | |
| Dova Pharmaceuticals | $10.87 | 2019 | |
| Veracyte, INC. | $0.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Alemar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.